Capricor Therapeutics’ (CAPR) “Neutral” Rating Reiterated at Roth Capital

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “neutral” rating restated by analysts at Roth Capital in a research note issued to investors on Friday, Benzinga reports. They presently have a $10.50 price target on the biotechnology company’s stock, up from their prior price target of $7.00. Roth Capital‘s price target suggests a potential upside of 12.41% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Piper Sandler upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, September 1st. B. Riley Financial upgraded shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $5.00 to $21.00 in a report on Monday, September 14th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Oppenheimer reissued an “outperform” rating on shares of Capricor Therapeutics in a research report on Thursday, October 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.09.

Capricor Therapeutics Trading Down 8.8%

NASDAQ CAPR opened at $9.34 on Friday. The business has a fifty day simple moving average of $8.10 and a 200 day simple moving average of $19.92. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The firm has a market capitalization of $543.09 million, a P/E ratio of -3.52 and a beta of 0.80.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29). As a group, sell-side analysts predict that Capricor Therapeutics will post -1.71 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in CAPR. Activest Wealth Management raised its position in Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 2,000 shares during the period. KBC Group NV purchased a new position in Capricor Therapeutics in the first quarter valued at about $44,000. Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 21.2% in the third quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 3,036 shares during the last quarter. VestGen Advisors LLC bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $191,000. Finally, SBI Securities Co. Ltd. grew its position in shares of Capricor Therapeutics by 834.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 23,495 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.